Alan Eisenman, a former money manager and financial planner from Houston, told jurors at Holmes’s criminal trial that he tried in vain for years to get straight answers about the blood-testing startup, only to see it ultimately collapse in 2018 while he was still holding his stake of about $1.2 million.
Eisenman’s testimony that he was more “proactive” than other stakeholders stands in contrast to previous witnesses who ...